Status:
SUSPENDED
The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine
Lead Sponsor:
Neurological Associates of West Los Angeles
Collaborating Sponsors:
Cell Surgical Network Inc.
Conditions:
Chronic Migraine, Headache
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The present study is being undertaken as a phase I study to determine the safety and feasibility of using adipose derived mesenchymal stem cell preparations (MSC) for treatment of CM. Intravenous and ...
Detailed Description
Chronic migraine (CM) is a disabling complex neurological disorder recognized as a complication of migraine in the the International Classification of Headache Disorders. Patients with CM experience h...
Eligibility Criteria
Inclusion
- Patients must exhibit symptoms that satisfy criteria of Chronic Migraine (e.g., experiencing headaches at least 15 days per month to a degree that is associated with significant disability and reduced health-related quality of life).
Exclusion
- Advanced stages of any terminal illness or active cancer that requires chemotherapy.
- Pregnancy, women who may become pregnant or are breastfeeding.
- Bleeding disorder, untreated.
Key Trial Info
Start Date :
August 16 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 16 2023
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04064879
Start Date
August 16 2018
End Date
August 16 2023
Last Update
September 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neurological Associates of West Los Angeles
Santa Monica, California, United States, 90403